These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 11535503)

  • 1. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
    Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
    Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
    J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras C; Vassilakopoulos TP; Vaiopoulos G; Siakantaris MP
    Med Oncol; 2001; 18(2):99-107. PubMed ID: 11778765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
    Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
    J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
    Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia.
    Bowen AL; Zomas A; Emmett E; Matutes E; Dyer MJ; Catovsky D
    Br J Haematol; 1997 Mar; 96(3):617-9. PubMed ID: 9054672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
    Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
    Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
    Osterborg A; Dyer MJ; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H
    J Clin Oncol; 1997 Apr; 15(4):1567-74. PubMed ID: 9193354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab in peripheral T-cell malignancies.
    Dearden C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
    Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
    Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
    Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
    Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
    Cao TM; Coutre SE
    Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
    J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
    Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
    Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat prolymphocytic leukemia.
    Dearden C
    Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
    Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
    Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
    J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT; Petruska PJ
    Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.